Abstract
Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Current Topics in Medicinal Chemistry
Title: Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity
Volume: 11 Issue: 21
Author(s): Chee Fei Chin, Daniel Yuan Qiang Wong, Ramasamy Jothibasu and Wee Han Ang
Affiliation:
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Abstract: Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Export Options
About this article
Cite this article as:
Fei Chin Chee, Yuan Qiang Wong Daniel, Jothibasu Ramasamy and Han Ang Wee, Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity, Current Topics in Medicinal Chemistry 2011; 11 (21) . https://dx.doi.org/10.2174/156802611798040778
DOI https://dx.doi.org/10.2174/156802611798040778 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Acute Cystitis Caused by Commensal Neisseria oralis: A Case Report and Review of the Literature
Infectious Disorders - Drug Targets Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Oncotargets in Different Renal Cancer Subtypes
Current Drug Targets Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Current Drug Metabolism Nanoparticles and Immune Cells
Current Pharmaceutical Design Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Current Hypertension Reviews MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies
Current Pharmaceutical Biotechnology Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets